Xvivo Perfusion (Sweden) Performance
| XVIVO Stock | SEK 451.50 5.50 1.23% |
The firm maintains a market beta of 0.87, which attests to possible diversification benefits within a given portfolio. Xvivo Perfusion returns are very sensitive to returns on the market. As the market goes up or down, Xvivo Perfusion is expected to follow. At this point, Xvivo Perfusion AB has a negative expected return of -0.21%. Please make sure to check out Xvivo Perfusion's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Xvivo Perfusion AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Xvivo Perfusion AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 354.2 M | |
| Total Cashflows From Investing Activities | -187.7 M |
Xvivo |
Xvivo Perfusion Relative Risk vs. Return Landscape
If you would invest 52,600 in Xvivo Perfusion AB on August 26, 2024 and sell it today you would lose (7,450) from holding Xvivo Perfusion AB or give up 14.16% of portfolio value over 90 days. Xvivo Perfusion AB is generating negative expected returns and assumes 2.0373% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than Xvivo, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Xvivo Perfusion Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xvivo Perfusion's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xvivo Perfusion AB, and traders can use it to determine the average amount a Xvivo Perfusion's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1034
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XVIVO |
Estimated Market Risk
| 2.04 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Xvivo Perfusion is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xvivo Perfusion by adding Xvivo Perfusion to a well-diversified portfolio.
Xvivo Perfusion Fundamentals Growth
Xvivo Stock prices reflect investors' perceptions of the future prospects and financial health of Xvivo Perfusion, and Xvivo Perfusion fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xvivo Stock performance.
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 5.54 B | |||
| Shares Outstanding | 29.83 M | |||
| Price To Earning | 662.55 X | |||
| Price To Book | 4.23 X | |||
| Price To Sales | 16.58 X | |||
| Revenue | 258.39 M | |||
| EBITDA | 39.2 M | |||
| Cash And Equivalents | 398.7 M | |||
| Cash Per Share | 7.45 X | |||
| Total Debt | 1.52 M | |||
| Debt To Equity | 1.20 % | |||
| Book Value Per Share | 47.94 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Earnings Per Share | 0.99 X | |||
| Total Asset | 1.54 B | |||
| Retained Earnings | 22 M | |||
| Current Asset | 98 M | |||
| Current Liabilities | 17 M | |||
About Xvivo Perfusion Performance
Assessing Xvivo Perfusion's fundamental ratios provides investors with valuable insights into Xvivo Perfusion's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Xvivo Perfusion is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Xvivo Perfusion AB , a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. Xvivo Perfusion AB was founded in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 45 people.Things to note about Xvivo Perfusion AB performance evaluation
Checking the ongoing alerts about Xvivo Perfusion for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xvivo Perfusion AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xvivo Perfusion AB generated a negative expected return over the last 90 days | |
| Xvivo Perfusion AB has accumulated about 398.7 M in cash with (12.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.45. | |
| Roughly 12.0% of the company outstanding shares are owned by insiders |
- Analyzing Xvivo Perfusion's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xvivo Perfusion's stock is overvalued or undervalued compared to its peers.
- Examining Xvivo Perfusion's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xvivo Perfusion's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xvivo Perfusion's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xvivo Perfusion's stock. These opinions can provide insight into Xvivo Perfusion's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Xvivo Stock Analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.